Physician profile
David H Smith
NPI 1386641082
$2,077.65
in general payments reported to CMS, 2019-2025
26 companies · $372 in 2025
The $372 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $96.60 · 2021: $137 · 2022: $76.15 · 2023: $350 · 2024: $668 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,369 · Education: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,369.20 |
| Education | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $359.94 | 2019-2025 | |
| Gilead Sciences, INC. | $240.08 | 2021-2025 | Trodelvy |
| Pfizer INC. | $180.15 | 2023-2025 | |
| Pharmaessentia USA Corporation | $126.37 | 2023-2025 | Besremi |
| Glaxosmithkline, LLC. | $121.39 | 2023-2025 | Ojjaara |
| Celgene Corporation | $114.52 | 2019-2024 | Reblozyl |
| Kite Pharma, INC. | $113.96 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $112.15 | 2021 | |
| Sobi, INC | $112.04 | 2024 | |
| Clovis Oncology, INC. | $99.95 | 2019 | |
| Seagen INC. | $71.89 | 2019-2022 | |
| Eisai INC. | $53.75 | 2024 | |
| Partner Therapeutics, INC. | $53.07 | 2019 | |
| Abbvie INC. | $43.90 | 2022-2024 | |
| Caris Mpi, INC. | $35.68 | 2025 | Mi Cancer Seek |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $34.70 | 2022-2024 | |
| Servier Pharmaceuticals LLC | $30.78 | 2025 | |
| Geron Corporation | $29.61 | 2024 | Rytelo |
| Alexion Pharmaceuticals, INC. | $23.07 | 2023 | Ultomiris |
| Astrazeneca Pharmaceuticals Lp | $21.89 | 2019 | |
| Incyte Corporation | $20.30 | 2020 | |
| Genzyme Corporation | $19.43 | 2019 | |
| Emd Serono, INC. | $19.05 | 2025 | |
| Daiichi Sankyo INC. | $14.61 | 2024 | Injectafer |
| Astellas Pharma US INC | $14.00 | 2023 | Xtandi |
| Amgen INC. | $11.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.